Navigation Links
Defensins neutralize anthrax toxin

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers. Their findings demonstrate a new mechanism by which EBV transforms human B cells from the immune system into cancerous cells, which can lead to development of B-cell lymphomas.

Erle S. Robertson, PhD, Associate Professor of Microbiology and Director of Tumor Virology, with Penn's Abramson Cancer Center and MD/PhD student Jason Knight, published their results in the early March issue of Molecular and Cellular Biology.

Using human cell cultures infected with the Epstein-Barr virus, the investigators found that a specific viral protein targets a molecule that normally regulates the cell-cycle progression, or duplication process, of resting B cells. In the presence of this viral protein ?called EBNA3C (for EBV nuclear antigen) ?the cell cycle of the usually quiescent human B cells gets a jump start, which ultimately initiates uncontrolled growth.

EBV, a member of the herpesvirus family and one of the most common human viruses, plays a role in cancers such as lymphoproliferative diseases in transplant or AIDS patients, Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma, and also causes the well-known disease, infectious mononucleosis. As many as 95 percent of adults 20 years and older have been infected with EBV, but show no symptoms.

"Viruses that are associated with cancers typically target the cell cycle to gain control," says Robertson. "However, this is the first time that laboratory research into how EBV drives the cancer process has directly identified a critical component of the cell cycle for control. Now we can develop targeted therapeutics to disrupt the function of this viral protein." The researchers surmise that the first use of future therapies from these studies will be in lymphoprolifera tive disease in transplant and immunocompromised patients because this is a clear case of EBV-driven B-cell lymphoma.

The use of peptides to block the interaction between this essential EBV protein and the specific pathway in human B cells is currently underway. Initial studies show that the growth of EBV-associated cancer cells can be inhibited in tissue-culture assays. The investigators are actively pursuing this line of investigation for developing potential therapies.



Related biology news :

1. Defensins Ward Off HIV In Two Ways
2. Bleach found to neutralize mold allergens
3. Scientists seek answers on what activates deadly anthrax spores
4. Antibodies from plants protect against anthrax
5. Critical step traced in anthrax infection
6. US Army plans to bulk-buy anthrax
7. New antibody shows promise as cure for anthrax
8. Effective, safe anthrax vaccine can be grown in tobacco plants
9. UCSD study finds anthrax toxins also harmful to fruit flies
10. Driver of anthrax toxicity could lead to late-stage therapy
11. Scientists design potent anthrax toxin inhibitor
Post Your Comments:

(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/9/2016)... an innovation leader in attendance control systems is proud to announce the introduction of ... make sure the right employees are actually signing in, and to even control the ... ... ... ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at . The ...
Breaking Biology Technology: